BioAtla, Inc.·Healthcare

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the “Share Consolidation”) of its common stock, par value $0.0001 per share (the “Common Stock”), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the “Effective Date”). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “BCAB” and is expected to begin trading on a split-adjusted basis when the market opens on April 6, 2026. Following the Share Consolidation, the new CUSIP number for the Common Stock will be 09077B203.

Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights. “As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and ensuring we maintain the flexibility to pursue all potential value‑creating options,” said Jay M.

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. Concurrently, the Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of our cost-containment measures. The Company intends to retain all employees essential for supporting value creation as part of its strategic review.

BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 2,697,341 shares, a decrease of 59.2% from the January 29th total of 6,612,587 shares. Currently, 4.8% of the company's shares are short sold. Based on an average

Shares of BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) have earned an average recommendation of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.